A PERSONALISED APPROACH TO IVF




Adverse Event reporting information can be found in footer
Request a Meeting
Delivering personalised medicine through individualised dosing.
The first human recombinant FSH:
A distinct glycosylation pattern compared with follitropin alpha leading to:
Individually dosed using the patient’s body weight and the ELECSYS® anti-Müllerian hormone (AMH) Plus immunoassay from Roche, ACCESS® AMH Advanced from Beckman Coulter or LUMIPULSE G® AMH from Fujirebio as a companion diagnostic1,2,3
Job Code: UK-RMMH-2400044 - Date of preparation: October 2024